Kinnate Biopharma KNTE

$ 2.65 0.0%

Annual report 2023
added 03-28-2024

Kinnate Biopharma Financial Statements 2011-2024 | KNTE

Annual Financial Statements Kinnate Biopharma

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	124 M	207 M	339 M	222 M	-	-	-	-	-	-	-	-	-
Shares	46.6 M	44.1 M	43.6 M	6.77 M	-	-	-	-	-	-	-	-	-
Historical Prices	2.66	4.69	7.78	33.4	-	-	-	-	-	-	-	-	-
Net Income	-113 M	-116 M	-89.8 M	-35.8 M	-12 M	-7.63 M	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-121 M	-119 M	-90.1 M	-36 M	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	240 K	-	-	-	-	-	-	-	-	-
EBITDA	-120 M	-118 M	-90 M	-35.9 M	-12 M	-7.63 M	-	-	-	-	-	-	-
Operating Expenses	121 M	119 M	90.1 M	36 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	28.2 M	30.4 M	22.9 M	6.76 M	3.06 M	1.96 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Kinnate Biopharma

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	47.1 M	46.7 M	45.4 M	44.3 M	44.2 M	44 M	43.9 M	43.9 M	43.7 M	43.5 M	43.5 M	43.5 M	3.75 M	3.71 M	3.67 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-30.7 M	-31.9 M	-32.9 M	-	-30.7 M	-27.1 M	-26.9 M	-	-24.7 M	-21.4 M	-17.5 M	-	-10.5 M	-7.61 M	-3.94 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-33.1 M	-34.1 M	-34.7 M	-	-31.4 M	-27.4 M	-27.1 M	-	-24.8 M	-21.6 M	-17.5 M	-	-10.5 M	-7.63 M	-4.15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-540 K	-548 K	-379 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-34.4 M	-	-31 M	-27.2 M	-27 M	-	-24.7 M	-21.5 M	-17.4 M	-	-10.4 M	-7.59 M	-4.14 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	33.1 M	34.1 M	34.7 M	-	31.4 M	27.4 M	27.1 M	-	24.8 M	21.6 M	17.5 M	-	10.5 M	7.63 M	4.15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	6.6 M	7.81 M	8.09 M	-	7.82 M	7.64 M	7.41 M	-	6.07 M	5.33 M	4.82 M	-	2.02 M	2.05 M	955 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency